Drug- and Herb-Induced Liver Injury in Clinical and Translational Hepatology: Causality Assessment Methods, Quo Vadis?
Overview
Affiliations
Drug-induced liver injury (DILI) and herb-induced liver injury (HILI) are typical diseases of clinical and translational hepatology. Their diagnosis is complex and requires an experienced clinician to translate basic science into clinical judgment and identify a valid causality algorithm. To prospectively assess causality starting on the day DILI or HILI is suspected, the best approach for physicians is to use the Council for International Organizations of Medical Sciences (CIOMS) scale in its original or preferably its updated version. The CIOMS scale is validated, liver-specific, structured, and quantitative, providing final causality grades based on scores of specific items for individual patients. These items include latency period, decline in liver values after treatment cessation, risk factors, co-medication, alternative diagnoses, hepatotoxicity track record of the suspected product, and unintentional re-exposure. Provided causality is established as probable or highly probable, data of the CIOMS scale with all individual items, a short clinical report, and complete raw data should be transmitted to the regulatory agencies, manufacturers, expert panels, and possibly to the scientific community for further refinement of the causality evaluation in a setting of retrospective expert opinion. Good-quality case data combined with thorough CIOMS-based assessment as a standardized approach should avert subsequent necessity for other complex causality assessment methods that may have inter-rater problems because of poor-quality data. In the future, the CIOMS scale will continue to be the preferred tool to assess causality of DILI and HILI cases and should be used consistently, both prospectively by physicians, and retrospectively for subsequent expert opinion if needed. For comparability and international harmonization, all parties assessing causality in DILI and HILI cases should attempt this standardized approach using the updated CIOMS scale.
Validation of the revised electronic version of RUCAM for diagnosis of DILI in Chinese patients.
Zhao X, Wang Y, Lai R, Wang X, Yu Y, Li M Hepatol Commun. 2024; 8(4).
PMID: 38466883 PMC: 10932528. DOI: 10.1097/HC9.0000000000000235.
Akimoto H, Nagashima T, Minagawa K, Hayakawa T, Takahashi Y, Asai S Front Pharmacol. 2022; 13:910205.
PMID: 35873565 PMC: 9298751. DOI: 10.3389/fphar.2022.910205.
Herb-Induced Liver Injury-A Challenging Diagnosis.
Nunes D, de Jesus Monteiro C, Dos Santos J Healthcare (Basel). 2022; 10(2).
PMID: 35206892 PMC: 8872293. DOI: 10.3390/healthcare10020278.
Teschke R, Zhu Y, Jing J J Clin Transl Hepatol. 2020; 8(2):200-214.
PMID: 32832401 PMC: 7438347. DOI: 10.14218/JCTH.2020.00009.
Agreement Among Different Scales for Causality Assessment in Drug-Induced Liver Injury.
Das S, Behera S, Xavier A, Velupula S, Dkhar S, Selvarajan S Clin Drug Investig. 2017; 38(3):211-218.
PMID: 29185238 DOI: 10.1007/s40261-017-0601-5.